In addition, NUTF2 was expected to provide a target for combination therapy as a novel treatment for cancers; in prostate cancer cells, it improved drug sensitivity and reduced cell proliferation; in melanoma, it downregulated factors that caused drug resistance [31, 32]. This evidence concerns the gene NUTF2 and melanoma.